Prognostic factors for maximally or optimally cytoreduced stage III nonserous epithelial ovarian carcinoma treated with carboplatin/paclitaxel chemotherapy-Reference-Cited by-同舟云学术

Prognostic factors for maximally or optimally cytoreduced stage III nonserous epithelial ovarian carcinoma treated with carboplatin/paclitaxel chemotherapy

Published:2018-05-04 Issue:7 Volume:44 Page:1284-1293
ISSN:1341-8076
Container-title:Journal of Obstetrics and Gynaecology Research
language:en
Short-container-title:J. Obstet. Gynaecol. Res.

Author:

Cuylan Zeliha F.¹,Meydanli Mehmet M.¹,Sari Mustafa E.¹,Akbayir Ozgur²,Celik Husnu³,Dede Murat⁴,Sahin Hanifi¹,Gungorduk Kemal⁵,Kuscu Esra⁶,Ozgul Nejat⁷,Gungor Tayfun¹,Ayhan Ali⁶

Affiliation:

1. Department of Gynecologic Oncology, Zekai Tahir Burak Women's Health Training and Research Hospital, Faculty of Medicine; University of Health Sciences; Ankara Turkey

2. Department of Gynecologic Oncology, Kanuni Sultan Suleyman Teaching and Research Hospital, Faculty of Medicine; University of Health Sciences; Istanbul Turkey

3. Division of Gynecologic Oncology, Department of Obstetrics and Gynecology, Faculty of Medicine; Baskent University; Adana Turkey

4. Department of Obstetrics and Gynecology, Gulhane Training and Research Hospital, Faculty of Medicine; University of Health Sciences; Ankara Turkey

5. Department of Gynecologic Oncology, Tepecik Education and Research Hospital, Faculty of Medicine; University of Health Sciences; Izmir Turkey

6. Division of Gynecologic Oncology, Department of Obstetrics and Gynecology, Faculty of Medicine; Baskent University; Ankara Turkey

7. Division of Gynecologic Oncology, Department of Obstetrics and Gynecology, Faculty of Medicine; Hacettepe University; Ankara Turkey

Publisher

Wiley

Subject

Obstetrics and Gynecology

Link

http://onlinelibrary.wiley.com/wol1/doi/10.1111/jog.13663/fullpdf

Reference31 articles.

1. Abridged republication of FIGO's staging classification for cancer of the ovary, fallopian tube, and peritoneum;Prat;Eur J Gynaecol Oncol,2015

2. Ovarian carcinoma subtypes are different diseases: Implications for biomarker studies;Kobel;PLoS Med,2008

3. Cyclophosphamide and cisplatin compared with paclitaxel and cisplatin in patients with stage III and stage IV ovarian cancer;McGuire;N Engl J Med,1996

4. Survival effect of maximal cytoreductive surgery for advanced ovarian carcinoma during the platinum era: A meta-analysis;Bristow;J Clin Oncol,2002

5. Mucinous but not clear cell histology is associated with inferior survival in patients with advanced stage ovarian carcinoma treated with platinum-paclitaxel chemotherapy;Bamias;Cancer,2010

Cited by 5 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. Residual Disease Threshold After Primary Surgical Treatment for Advanced Epithelial Ovarian Cancer, Part 1: A Systematic Review and Network Meta-Analysis;American Journal of Therapeutics;2022-12-20

2. Impact of residual disease as a prognostic factor for survival in women with advanced epithelial ovarian cancer after primary surgery;Cochrane Database of Systematic Reviews;2022-09-26

3. NIPEC with Single-Dose Intraperitoneal Cisplatin and Paclitaxel in Stage III Epithelial Ovarian Cancer;South Asian Journal of Cancer;2022-08-15

4. CXCR4 and RIF1 overexpression induces resistance of epithelial ovarian cancer to cisplatin-based chemotherapy;Journal of Cancer Research and Therapeutics;2021

5. Response to Multi-Line Chemotherapy in Non-Serous Epithelial Ovarian Cancer;Journal of Obstetrics and Gynaecology Canada;2020-10